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Abstract
RNA interference (RNAi) is a major antiviral pathway that shapes evolution of RNA viruses. We show here that Nora virus, a
natural Drosophila pathogen, is both a target and suppressor of RNAi. We detected viral small RNAs with a signature of
Dicer-2 dependent small interfering RNAs in Nora virus infected Drosophila. Furthermore, we demonstrate that the Nora
virus VP1 protein contains RNAi suppressive activity in vitro and in vivo that enhances pathogenicity of recombinant Sindbis
virus in an RNAi dependent manner. Nora virus VP1 and the viral suppressor of RNAi of Cricket paralysis virus (1A)
antagonized Argonaute-2 (AGO2) Slicer activity of RNA induced silencing complexes pre-loaded with a methylated single-
stranded guide strand. The convergent evolution of AGO2 suppression in two unrelated insect RNA viruses highlights the
importance of AGO2 in antiviral defense.
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Introduction
An efficient antiviral immune response is essential for the
control or elimination of virus infection and for survival of the
infected host. The immune system exerts a strong evolutionary
pressure that shapes the genetic makeup of viral pathogens.
Indeed, viruses evolved counter-defense mechanisms to evade,
suppress or inactivate host immunity. Studying these mechanisms
provides important insight in the critical steps of antiviral
responses and may uncover novel components and regulators of
immune pathways.
Plants, fungi, and invertebrate animals rely on the RNA
interference (RNAi) pathway for antiviral defense [1,2]. The initial
trigger of an antiviral RNAi response is the recognition and
cleavage of viral double-stranded RNA (dsRNA) into viral small
interfering RNAs (vsiRNAs), in insects by the ribonuclease Dicer-2
(Dcr-2). These vsiRNAs act as specificity determinants of the
Argonaute-2 (AGO2) containing effector nuclease complex RISC
(RNA induced silencing complex). RISC maturation involves a
number of sequential steps: loading of the vsiRNA into AGO2,
cleavage and elimination of the passenger RNA strand, and 29-O-
methylation of the 39-terminal nucleotide of the retained guide
strand. It is thought that vsiRNA-loaded RISC subsequently
cleaves viral target RNA (Slicer activity). The hypersensitivity to
viral infections of AGO2 mutant flies and of AGO2 knockdown
mosquitoes provides genetic support for this hypothesis [3–7].
Nevertheless, direct evidence supporting this model, for example
by the detection of viral Slicer products, is lacking.
The evolution of viral suppressors of RNAi (VSRs) is a
testament to the antiviral potential of the RNAi pathway in plants
and insects. Given the central role of dsRNA and siRNAs as
initiators and specificity determinants of the RNAi pathway, it is
not surprising that many VSRs sequester dsRNA. For instance,
the Drosophila C virus (DCV) 1A protein binds long dsRNA and
shields it from processing by Dcr-2 [6]. Flock House virus (FHV)
B2 displays a dual RNA binding activity: it binds long dsRNA as
well as siRNAs, thereby preventing their incorporation into RISC
[8–10]. Similarly, many plant VSRs display dsRNA binding
activities, leading to the hypothesis that dsRNA or siRNA binding
is a general mechanism for RNAi suppression [11,12]. Neverthe-
less, other mechanisms have been reported [1]. The RNAi
suppressive activity of the Cricket paralysis virus (CrPV) 1A
protein, for example, relies on a direct interaction with AGO2
[13].
VSRs have been identified in dozens of plant viruses from all
major virus families [1]. In contrast, VSRs have thus far been
identified in only three insect RNA viruses (FHV, CrPV, and
DCV). These VSRs were characterized using genetic and
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biochemical approaches in the model organism Drosophila
melanogaster. While these viruses indeed efficiently infect Drosophila
laboratory stocks and cell lines, DCV is the only natural Drosophila
pathogen among these three viruses [14,15]. Although FHV and
CrPV have a remarkable broad host range in the laboratory, they
were originally isolated from non-Drosophilid host species: the
New Zealand grass grub (Costelytra zealandica) and field crickets
(Teleogryllus oceanicus and T. commodus), respectively [16–19].
Since viral counter-defense mechanisms co-evolve with the
antiviral immune responses of the host species, it is essential to
characterize a VSR within the correct evolutionary context. We
therefore set out to identify an RNAi suppressor in Nora virus, a
positive sense (+) RNA virus that persistently infects Drosophila
laboratory stocks as well as Drosophila in the wild [20] (D.J.
Obbard, personal communication). The genome organization and
phylogeny suggest that Nora virus is the type member of a novel
virus family within the order of Picornavirales [20]. Here we show
that Nora virus VP1, the protein product of open reading frame 1
(ORF1), suppresses RNAi in cell culture as well as in flies. In
accordance, VP1 is an RNAi-dependent viral pathogenicity factor.
In a series of biochemical assays, we show that both Nora virus
VP1 as well as CrPV 1A inhibit Slicer activity of a pre-assembled
RISC loaded with a methylated guide strand. The lack of amino
acid sequence similarity between CrPV 1A and Nora virus VP1
suggests that their Slicer antagonistic activities resulted from
convergent evolution, providing direct support for the critical role
of AGO2 Slicer activity in antiviral defense.
Results
Nora virus is a target of RNAi in vivo
Nora virus is an enteric (+) RNA virus that successfully
establishes a persistent infection in flies [20]. The mechanism by
which this virus establishes persistent infections is unknown. To
determine whether Nora virus is a target for Dcr-2, we analyzed
the presence of Nora virus small RNAs in the w1118 Drosophila
strain that is widely used as a recipient strain for transgenesis.
We isolated and sequenced 19–29 nt small RNAs from body
(abdomen and thorax), thorax and head of adult w1118 flies.
Sequence reads that perfectly matched the Drosophila genome were
annotated and discarded. Of the remaining reads, 396.646 (7,8%,
body), 237.265 (10,6%, thorax), and 1.099.496 (7,7%, head)
matched the published Nora virus sequence (NC_007919.3),
indicating that the w1118 strain was infected by Nora virus
(Table 1). As RNA viruses rapidly evolve, viral small RNA
sequences may have been missed in this initial matching step. We
therefore reconstituted the Nora virus genome through an iterative
alignment/consensus treatment of the viral small RNA sequences
in our libraries [21]. The reconstituted Nora virus genome (rNora
virus) differed at only 3.2% of the nucleotides from the published
genome sequence. Aligning small RNAs to the rNora virus
genome instead of the published Nora virus sequence resulted in
an increased number of viral reads in the three libraries (,121%,
Table 1). We therefore used the reconstituted genome as a
reference genome in further analyses.
In all three libraries, Nora virus-derived small RNAs were
predominantly 21-nt long, the typical size of Dicer-2 products.
The size distribution of small RNAs derived from the (+) RNA
strand, however, were noticeably wider than those derived from
the (2) RNA strand (Figure 1A). For 21-nt viral RNA reads, there
was only a slight bias towards (+) small RNAs (ratio (+) RNA/total
RNA ,0.58), whereas small RNAs of other sizes were predom-
inantly derived from the (+) strand (Figure 1B). In all three
libraries, the 21-nt Nora virus-derived RNAs are distributed across
the genome, covering both the (+) and (2) viral RNA strands with
approximately equal numbers (Figure 1C). These data suggest that
dsRNA replication intermediates of Nora virus are processed into
21-nt long siRNAs. The origin of the other size classes of viral
small RNAs remains unclear. However, as the predominance of
(+) over (2) small RNA reads is reminiscent of the excess of (+)
over (2) viral (full-length) RNA that is typically observed in (+)
RNA virus infection, they may be due to non-specific RNA
degradation.
Drosophila Dcr-2 generates 21-nt duplex siRNAs in which 19
nucleotides are base-paired leaving a 2-nt 39 overhang at each end.
For each library, we collected the 21-nt RNA reads whose 59 ends
overlapped with another 21-nt RNA read on the opposite strand
of the Nora virus genome. Then, for each possible overlap of 1 to
21-nt, the numbers of read pairs were counted and converted into
Z-scores (Figure 1D). This analysis revealed that 21-nt Nora virus-
derived RNAs in body and thorax libraries tend to overlap by 19-
nt, which is a typical feature of siRNA duplex precursors. This
siRNA duplex signature was observed to a lesser extent in head
Table 1. Annotation of small RNA sequences in libraries from
body (abdomen and thorax), thorax, and head of Nora virus
infected w1118 adult flies.
Body Thorax Head
Total library 18.296.275 17.280.520 49.633.458
Match to D. melanogaster* 13.184.119 15.033.831 35.435.546
Unmatched* 5.112.156 2.246.689 14.197.912
Nora virus (NC_007919.3)* 396.646 237.265 1.099.496
Nora virus (reconstituted)* 479.572 291.045 1.329.336
*The number of reads matching the Drosophila genome, reads that fail to map
to the Drosophila genome (unmatched), and reads mapping to the Nora virus
genome (isolate Umea 2007) and the reconstituted Nora virus genome are
indicated for each library.
doi:10.1371/journal.ppat.1002872.t001
Author Summary
Multi-cellular organisms require a potent immune re-
sponse to ensure survival under the ongoing assault by
microbial pathogens. Co-evolution of virus and host
shapes the genome of both pathogen and host. Using
Drosophila melanogaster as a model, we study virus-host
interactions in infections by Nora virus, a non-lethal natural
pathogen of fruit flies. Insects depend on the RNA
interference (RNAi) pathway for antiviral defense. A
hallmark of the antiviral RNAi response is the production
of viral small RNAs during infection. We detected Nora
virus small RNAs during infection of Drosophila, demon-
strating that Nora virus is a target of the antiviral RNAi
pathway. Furthermore, we show that Nora virus viral
protein 1 (VP1) inhibits the catalytic activity of Argonaute-
2, a key protein of the RNAi pathway. The 1A protein of
Cricket paralysis virus suppresses RNAi via a similar
mechanism. Importantly, whereas Nora virus persistently
infects Drosophila, Cricket paralysis virus induces a lethal
infection. Our findings thus indicate that two distantly
related viruses independently evolved an RNAi suppressor
protein that targets the Argonaute-2 protein. Altogether,
our results emphasize the critical role of Argonaute-2 in
insect antiviral defense, both in lethal and persistent
infections.
Nora Virus VP1 Suppresses Argonaute-2 Activity
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Figure 1. Nora virus is targeted by RNAi in adult flies. (A) Size distribution of Nora virus-derived small RNAs in libraries from thoraxes, bodies
and heads of w1118 flies. Read counts of small RNAs matching the (+) and (2) viral RNA strands are in gray and black, respectively. (B) Proportion of (+)
Nora virus small RNA reads of total viral reads. Frequencies were computed from the distributions in panel A for each size class. (C) Viral siRNA
distribution across the viral genome. The abundance of 21-nt small RNAs matching the (+) and (2) viral RNA strands of the reconstituted Nora virus
(rNora) reference genome is shown in gray and black, respectively. (D) Z-scores for the number of overlapping pairs of sense and antisense 21-nt
Nora virus small RNAs matching the rNora virus reference genome. For each possible overlap of 1 to 21-nt, the number of read pairs was counted and
converted into a Z-score.
doi:10.1371/journal.ppat.1002872.g001
Nora Virus VP1 Suppresses Argonaute-2 Activity
PLOS Pathogens | www.plospathogens.org 3 August 2012 | Volume 8 | Issue 8 | e1002872
libraries. Very little Nora virus RNA can be detected in the head
[22], yet vsiRNA levels were similar in head, thorax, and body
(Table 1). The origin of the vsiRNAs in the head and the reason
for the less pronounced vsiRNA signature of those small RNAs
remain unclear. Altogether, our results strongly suggest that Nora
virus double-stranded replication intermediates are processed by
Dcr-2 into vsiRNAs that trigger an RNAi response in infected flies.
Nora virus VP1 suppresses RNAi in vitro
Our small RNA profiles indicate that Nora virus is targeted by
Dcr-2. Nevertheless, the virus efficiently establishes a persistent
infection, suggesting that it is able to evade or suppress the
antiviral RNAi response. The Nora virus genome contains four
open reading frames (ORFs) (Figure 2A). Nora virus ORF2 is
predicted to encode the helicase, protease, and polymerase
domains that together form a picornavirus-like replication cassette.
ORF4 encodes three proteins that make up the Nora virus capsid
(VP4A, VP4B, and VP4C) [23]. To determine whether the Nora
virus genome encodes an RNAi suppressor, we analyzed the four
ORFs in an RNAi sensor assay in Drosophila cell culture (Figure 2B–
2D). In this assay, S2 cells are transfected with firefly (Fluc) and
Renilla luciferase (RLuc) reporter plasmids and a plasmid that
expresses one of the four viral ORFs. Subsequently, Fluc
expression is silenced using specific dsRNA, and Fluc and Rluc
activity is monitored. As expected, DCV 1A, a well characterized
VSR that binds long dsRNA, efficiently suppressed RNAi,
whereas the inactive DCV 1A K73A mutant was unable to do
so (Figure 2C and [6]). Cotransfection of the ORF1 expression
plasmid also resulted in de-repression of Fluc, suggesting that VP1,
the protein product of ORF1, is a suppressor of RNAi. Expression
of ORF3 and ORF4 did not affect Fluc activity (Figure 2C).
However, since expression of ORF2 and the production of mature
capsid proteins from ORF4 were not detectable on western blot,
we cannot exclude the possibility that these protein products are
able to suppress RNAi as well (Figure 2B).
Next, we tested whether VP1 inhibits the production of siRNAs
by Dcr-2 or a subsequent step in the RNAi pathway. To this end,
we repeated the RNAi sensor assay using a synthetic siRNA that
does not require Dcr-2 cleavage for its silencing activity. Also
under these conditions, Nora virus VP1 suppressed silencing of the
Fluc reporter. Furthermore, VP1 suppressed RNAi to a similar
extent as CrPV 1A, which was previously shown to suppress the
effector stage of the RNAi machinery [13] (Figure 2D).
In Drosophila, the microRNA (miRNA) and siRNA pathways are
separate processes, with Dcr-1 and AGO1 dedicated to the
miRNA pathway and Dcr-2 and AGO2 to the siRNA pathway.
Nevertheless, crosstalk between the miRNA and RNAi pathways
occurs. Using miRNA sensor assays in S2 cells, in which Fluc
expression is silenced by endogenous miRNAs or co-expressed
primary miRNAs, we observed that VP1 does not suppress
miRNA activity (Text S1 and Figure S1). Together, these data
indicate that VP1 is able to suppress the RNAi, but not the
miRNA pathway, at a step after dsRNA processing by Dcr-2.
The C-terminus of VP1 is essential for its suppressor
activity
VP1 is highly conserved among different Nora virus isolates
(Figure S2). We were unable to predict a protein domain in VP1
suggestive of a mechanism of action. Furthermore, we did not
obtain a significant alignment to any other protein from the non-
redundant protein sequence database. To map the VSR region of
VP1, we generated a series of N- and C-terminal (DN and DC)
truncations and tested them in the RNAi reporter assay in S2 cells
(Figures 3A and S3). With the exception of the VP1DN390 and
VP1DN418 mutants, in which no protein could be detected on
Western blot, all VP1DN and VP1DC constructs produced proteins
of the expected size (Figure 3B). Deletion of 74 amino acids (aa) or
more from the C-terminus of VP1 resulted in loss of suppressor
activity (Figure 3C). This suggests that the active domain of VP1
resides in its C-terminal region. Indeed, deleting up to 351 aa from
the N-terminus (VP1DN351), out of a total of 475 aa, did not affect
VSR activity. These results show that the RNAi suppressor activity
of VP1 maps to the C-terminal 124 aa.
VP1 is an RNAi suppressor in vivo
We next evaluated the VSR activity of Nora virus VP1 in vivo
using transgenic flies in which thread (th), also known as Drosophila
inhibitor of apoptosis 1, can be silenced by expression of dsRNA
targeting this gene (thRNAi [24,25]) (Figure 4). Eye-specific
expression of thRNAi using the GMR-Gal4 driver leads to severe
apoptosis in the developing eye. As a consequence, thRNAi flies
display a reduced eye size, loss of eye pigmentation, and
roughening of the eye surface (Figure 4A, results are shown for
AGO2321 heterozygotes; thRNAi in a wildtype background shows the
same phenotype, data not shown and ref. 24). Silencing of th in the
eye of thRNAi flies is fully dependent on the RNAi pathway, since
the phenotype is lost in an AGO2 null mutant background
(Figure 4B). These results indicate that the thRNAi sensor fly is a
robust system to monitor RNAi activity in vivo.
Consistent with its RNAi suppressive activity in cell culture,
expression of full-length VP1 (VP1FL) in thRNAi flies resulted in eyes
with a normal size and a rescue of the rough eye phenotype
(Figure 4C). The phenotype of thRNAi flies expressing the VP1DC74
mutant was similar to that of flies expressing GFP as a negative
control, confirming that this mutant is functionally inactive
(Figure 4D, E). Notably, while VP1 only partially rescued the
RNAi-dependent phenotype, CrPV 1A fully reverted the thRNAi
induced phenotype (Figure 4F). Whether this difference is due to a
more robust RNAi suppressive activity of CrPV 1A or to a
difference in expression level remains to be established.
VP1 enhances viral pathogenicity in vivo
Having established that VP1 displays RNAi suppressive activity
in vitro and in vivo, we next analyzed the effect of VP1 on viral
pathogenicity in adult flies. To this end, we generated recombi-
nant Sindbis virus (SINV) expressing the functional VP1DN351
(SINV-VP1) or GFP (SINV-GFP) from a second subgenomic
promoter (Figure 5A). Although arboviruses are a target of the
RNAi pathway during infection in insects [3,5,26], we and others
have not detected VSR activity in infections with SINV and the
related alphavirus Semliki Forest virus [27,28] (data not shown).
Indeed, SINV recombinants expressing the viral RNAi suppres-
sors FHV B2 and CrPV 1A were significantly more pathogenic
than their controls in mosquitoes and Drosophila, respectively
[13,27].
We injected wildtype w1118 flies with the SINV recombinants
and monitored survival over time. SINV-GFP (and the parental
SINV virus, data not shown) induced only modest mortality in
these flies with a fully functional RNAi response. After 36 days of
infection, 73% of the SINV-GFP infected flies and all mock
infected flies were still alive. In contrast, SINV-VP1 infection
resulted in more severe mortality. SINV-VP1 infected flies died
faster and only 9% of the flies survived the 36-days follow up
period (Figure 5B). Although these results indicate that VP1
enhances viral pathogenicity, they fail to show that this effect
depends on its VSR activity. Viral proteins are often multifunc-
tional and the effect of VP1 on the course of infection might be
attributed to another, as yet unknown, activity of VP1. We
Nora Virus VP1 Suppresses Argonaute-2 Activity
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therefore performed recombinant SINV infections in RNAi
deficient Dcr-2 mutant flies. In this genetic background, an RNAi
suppressor is not expected to enhance pathogenicity of the virus.
Upon infection with SINV-GFP, the Dcr-2 mutants died much
faster than wild-type flies, confirming that SINV is indeed a target
of the RNAi pathway. In contrast to infections in RNAi competent
flies, the course of infection of SINV-VP1 and SINV-GFP was
remarkably similar in Dcr-2 mutants, with 100% mortality at 22
days after infection in both cases (Figure 5C). We therefore
conclude that VP1 enhances virulence of an RNA virus in vivo
through its RNAi suppressive activity.
Nora virus VP1 interferes with the effector phase of RNAi
To further characterize the VSR activity of Nora virus VP1, we
next analyzed the activity of VP1 in a series of biochemical assays
that monitor individual steps of the RNAi pathway. To this end,
we fused the active VP1DN284 mutant to the maltose binding
protein (MBP-VP1) and purified it from Escherichia coli. We verified
that MBP-VP1 fusion proteins are fully functional in VSR assays
in S2 cells to exclude the possibility that MBP interferes with VP1
VSR activity (data not shown).
The ability of VP1 to suppress siRNA-initiated RNAi in S2 cells
(Figure 2D) suggests that VP1 inhibits a step downstream of
siRNA production by Dcr-2. In accordance, recombinant VP1
was unable to bind long dsRNA in gel mobility shift assays and
could not interfere with Dcr-2 mediated processing of long dsRNA
into siRNAs in S2 cell extract (Figure S4A, B). We next analyzed
whether VP1 is able to bind siRNAs in a gel mobility shift assay.
As a positive control, we used a fusion protein of MBP and the
Rice hoja blanca virus non-structural protein 3 (NS3), which binds
duplex siRNAs with high affinity [29]. Whereas NS3 efficiently
bound siRNAs in our assays, we were unable to observe a shift in
mobility of siRNAs after incubation with VP1, even at the highest
concentrations used (Figure 6A).
Figure 2. Nora virus VP1 suppresses RNAi in vitro. (A) Schematic representation of the Nora virus genome with its four predicted ORFs in three
different reading frames. There is a 7-nt overlap between ORF1 and ORF2 and a 26-nt overlap between ORF2 with ORF3. An intergenic region of 85 nt
separates ORF3 and ORF4. (B) Western blot analysis of V5-epitope tagged Nora virus expression constructs. Two days after transfection of the
indicated plasmids into S2 cells, expression of the constructs was analyzed by Western blot using the V5 antibody (aV5). Asterisks (*) indicate
additional bands that do not correspond to the expected size of the full-length protein product. (C) RNAi reporter assay in Drosophila S2 cells.
Copper-inducible plasmids encoding Fluc and Rluc were transfected into S2 cells together with a construct expressing Nora virus ORF1, 3, and 4,
encoding viral protein 1 (VP1), VP3, and VP4, respectively. Two days after transfection, dsRNA targeting Fluc or GFP (Ctrl) was added to the medium.
Seven hours later, expression of FLuc and Rluc was induced and luciferase activity was measured the next day. FLuc counts were normalized to Rluc
counts and presented as fold silencing relative to the control GFP dsRNA. Plasmids encoding DCV 1A and the K73A mutant (DCV 1A mut) were used
as controls. (D) siRNA-based RNAi reporter assay. The experiment was performed as described in panel C, but 21-nt Fluc siRNAs were cotransfected
with the reporter plasmids to silence gene expression. An siRNA targeting the human MDA5 gene was used as a non-silencing control (Ctrl). Bars in
panel C represent averages and standard deviations of five independent samples; bars in panel D represent averages and standard deviations of
three independent samples. Panel C and D are representative for two and three independent experiments, respectively.
doi:10.1371/journal.ppat.1002872.g002
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PLOS Pathogens | www.plospathogens.org 5 August 2012 | Volume 8 | Issue 8 | e1002872
Since VP1 is incapable of interfering with the initiator phase of
the RNAi pathway, we next examined the effect of VP1 on the
effector phase of RNAi. For this purpose, we used an in vitro RNA
cleavage assay (Slicer assay) in Drosophila embryo extract [30], in
which a sequence-specific siRNA triggers cleavage of a target
RNA. Since the 59 cap of the target RNA is radioactively labeled,
the 59 cleavage product can be visualized by autoradiography after
separation on a denaturing polyacrylamide gel. Indeed, a cleavage
product of the expected size was detected if embryo extract was
incubated with a target RNA and a specific siRNA. Specific
cleavage products were not generated in the presence of a non-
specific control siRNA (Figure 6B, lanes 1 and 2). Recombinant
VP1 protein, but not control MBP protein, efficiently inhibited the
production of cleavage product (Figure 6B, lanes 3 and 4). We
note, however, that a minor fraction of the target RNA is still
cleaved in the presence of VP1 (Figure 6B, lane 3). Together, these
experiments show that VP1 does not affect the initiator phase of
the RNAi pathway, but interferes with RISC activity.
Figure 3. The C-terminus of Nora virus VP1 is essential for RNAi suppressor activity. (A) Schematic presentation of full-length (FL) and N-
and C-terminal deletion mutants (DN and DC) of VP1. (B) Western blot analysis of VP1 expression constructs. V5 epitope tagged expression constructs
were transfected into Drosophila S2 cells and expression of VP1FL and the deletion mutants was analyzed by Western blot using a V5 antibody (aV5).
(C) RNAi reporter assay in S2 cells. The experiment was performed as described in the legend to Figure 2D, using plasmids encoding either CrPV 1A,
VP1FL or the VP1 deletion mutants. Bars represent averages and standard deviations of three independent samples. The graph is representative for
two independent experiments.
doi:10.1371/journal.ppat.1002872.g003
Nora Virus VP1 Suppresses Argonaute-2 Activity
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Nora virus VP1 inhibits RISC activity of pre-assembled
mature RISC
To discriminate between RISC assembly and target RNA
cleavage by a pre-assembled RISC complex, we performed Slicer
assays under two experimental conditions (Figure 7A). In the first
approach, a purified suppressor protein is added 30 minutes
before the siRNA, which allows us to analyze the effect of the VSR
on both RISC loading and target cleavage. In the second
approach, the embryo extract is incubated with siRNAs for
30 minutes before addition of recombinant protein. This second
protocol allows a mature RISC to form prior to the addition of a
VSR, thereby allowing us to assess the effect of the VSR on slicing
only. As CrPV 1A was previously shown to affect the effector
phase of the RNAi pathway [13], we generated recombinant
GST-CrPV 1A as well as control GST. These proteins were
included in our assays.
Using the first protocol, cleavage of the target RNA was
suppressed by VP1 (Figure 7B, lane 3). Strikingly, VP1 was also
able to inhibit target cleavage when added to an embryo lysate
containing pre-loaded RISC (Figure 7B, lane 7). The observed
suppression of slicing was VP1 specific, since MBP alone did not
inhibit RNA cleavage (lane 4 and 8). Recombinant CrPV 1A also
suppressed slicing in both experimental procedures (Figure 7B,
lanes 5 and 9).
To determine if VP1 affects the protein stability of AGO2, we
incubated the recombinant proteins in Drosophila embryo extract
and analyzed endogenous AGO2 protein levels by Western blot.
Neither VP1 nor CrPV 1A affected AGO2 protein levels in
embryo lysate, indicating that these two proteins do not mediate
RNAi suppression through degradation of AGO2 (Figure 7C).
To further confirm the inhibitory effect of VP1 on Slicer activity
rather than RISC assembly, we performed Slicer assays using
different siRNA guides. During RISC maturation, guide strands in
AGO2 are 29-O-methylated at their 39 terminal nucleotide by the
Drosophila methyltransferase Hen1 [31]. This modification protects
AGO2 associated siRNAs from degradation by trimming and
tailing events that occur when there is extensive base-pairing of the
guide RNA with a target RNA [32]. To overcome a requirement
for Hen1, an siRNA bearing a 29-O-methylated 39-terminal
nucleotide on the guide strand was used in Slicer assays. Similar to
Figure 4. VP1 suppresses RNAi in vivo. (A–F) RNAi of Drosophila Inhibitor of Apoptosis1/thread (th) in the eye of adult flies in the indicated genetic
background or in the presence of several transgene constructs. RNAi-mediated knockdown of th results in a reduced size and pigmentation of the
eye and roughening of the eye surface in AGO2321 heterozygotes (A), but not in AGO2321 homozygotes (B). Eye phenotype of transgenic flies co-
expressing the thRNAi construct and Nora virus full-length VP1 (VP1 FL, C), a C-terminal deletion mutant of VP1 (VP1DC74, D), GFP (E) or CrPV 1A (F).
Maximum silencing of th was examined in the presence of the GFP control transgene (E). For each line, five representative pictures of eyes of two- to
four-day-old male flies are presented. Pictures are representative for three independent experiments.
doi:10.1371/journal.ppat.1002872.g004
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the non-methylated siRNA, the methylated siRNA produced a
specific cleavage product of the expected size (Figure 7D, lane 2).
Both Nora virus VP1 and CrPV 1A inhibited the cleavage activity of
RISC that was pre-loaded with the methylated siRNA (Figure 7D,
lane 3 and 5). Again, the GST and MBP control proteins were
unable to affect Slicer activity (Figure 7D, lane 4 and 6).
After loading of the siRNA as a duplex, AGO2 cleaves the
passenger strand which is then degraded by the C3PO nuclease
complex [33]. To circumvent canonical loading of RISC, we
induced RISC formation with a single-stranded methylated guide
RNA. Although less efficient, loading of single-stranded guide
strands into AGO2 is possible via a bypass mechanism [34,35].
Indeed, at high concentrations, methylated single-stranded guide
RNA induced specific cleavage of cap-labeled target RNA
(Figure 7E, lane 2). Interestingly, single-stranded guide RNA-
induced target cleavage was specifically inhibited both by Nora
virus VP1 and by CrPV 1A (Figure 7E, lanes 3 and 5). These
results indicate that both CrPV 1A and Nora virus VP1 inhibit
Slicer activity of mature RISC rather than RISC assembly.
Following maturation, RISC binds, cleaves, and releases
complementary target RNA, and returns to a Slicer-competent
state. Drosophila RISC is a multiple turnover complex, in which
release of the cleaved target RNA is a rate-limiting step that is
greatly enhanced by ATP [36]. We therefore analyzed suppression
of Slicer activity under ATP-limiting conditions with a 20-fold
molar excess of siRNA over target RNA. RISC was loaded in the
presence of ATP, after which creatine kinase was inactivated by
NEM, and ATP was depleted (2ATP) by addition of hexokinase
and glucose (Figure S5). In parallel, ATP levels were restored
(+ATP) after NEM treatment by adding back creatine kinase, and
omitting hexokinase treatment. As expected, RISC shows a lower
cleavage rate in –ATP conditions than in +ATP conditions
(Figure 7F, compare lanes 3 and 5 with lanes 8 and 10). Even
under –ATP conditions, Nora virus VP1 and CrPV 1A were able
to inhibit Slicer activity (Figure 7F, lanes 2 and 4), suggesting that
these two VSRs inhibit the catalytic target cleavage by AGO2.
Discussion
The mechanisms by which RNA viruses evade sterilizing
immunity and establish chronic persistent infections remain poorly
understood [37]. Nora virus successfully establishes a persistent
infection in Drosophila, providing an excellent model to study
mechanisms of persistence. We show here that Nora virus is a
target of the antiviral RNAi machinery and that it encodes a
potent suppressor of RNAi. Of note, Nora virus RNA levels are
unaffected by mutations in the RNAi pathway [38]. These
observations therefore suggest that dynamic interactions between
the antiviral RNAi response and viral counter-defense mechanisms
determine viral persistence.
The production of viral siRNAs is a hallmark of an antiviral
RNAi response. By detection of Nora virus-derived vsiRNAs in
infected fly stocks, we provide direct evidence that Nora virus is a
target of Dcr-2. Nora virus vsiRNAs are distributed across the viral
genome, with similar amounts derived from the (+) and (2) RNA
strands. During (+) RNA virus infection, (+) viral RNA accumulates
in large excess over (2) viral RNA (,50–100 fold). Cleavage of
structured RNA elements by Dcr-2 is therefore expected to produce
viral small RNAs that mirror this asymmetric distribution. Thus,
similar to other RNA viruses, our results imply that Dcr-2 targets
the dsRNA intermediates in Nora virus replication [2,4,39–41].
The current model proposes that the antiviral RNAi response
relies on dicing of viral dsRNA and on slicing of viral target RNAs
using vsiRNAs as a guide. Genetic analyses support the role of
Figure 5. VP1 enhances viral pathogenicity via its RNAi
suppressive activity. (A) Schematic representation of Sindbis virus
(SINV) and SINV recombinant containing a duplicated subgenomic
promoter (sg1 and sg2) driving expression of a viral suppressor of RNAi
(VSR). (B and C) Survival curves of w1118 wildtype flies (B) and Dcr-2L811fsX
mutants (C) infected with SINV recombinants expressing either GFP (black
diamond) or VP1DN351 (gray triangle), or mock infected (black square).
Survival curves are representative of two independent experiments.
doi:10.1371/journal.ppat.1002872.g005
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AGO2 in antiviral defense: AGO2 mutants are hypersensitive to a
number of RNA virus infections [3–7,42]. Yet, interpretation of
this AGO2 phenotype is complicated by other cellular functions of
AGO2, such as regulation of cellular gene transcription and
control of transposon activity [43–45]. An alternative model
proposes that dicing of double-stranded replication intermediates
plays an important role in latent virus infection [46]. Dicing of an
essential replication intermediate by Dicer-2 should theoretically
be sufficient to abort a productive virus replication cycle. The
convergent evolution of VSRs that suppress the catalytic activity of
AGO2 in two distantly related RNA viruses, Nora virus and
CrPV, underlines the essential role of AGO2 Slicer activity in
antiviral defense, also in persistent infections in vivo. Importantly,
these two viruses display a strikingly different course of infection –
CrPV causes a lethal infection, whereas Nora virus establishes a
non-lethal, persistent infection – suggesting that the interaction
between a VSR and the host RNAi machinery is not the main
determinant for viral pathogenicity.
Materials and Methods
Small RNA sequencing and analysis
Total RNA was extracted from dissected heads, bodies
(abdomens and thoraxes) and thoraxes from w1118 male flies using
Trizol reagent (Invitrogen), and RNA quality was verified on a
Bioanalyzer (Agilent). Small RNAs were then cloned using the
DGE-Small RNA Sample Prep Kit and the Small RNA v1.5
Sample Preparation Kit (Illumina) following the manufacturer’s
instructions. Libraries were sequenced on the Illumina HiSeq
platform.
Sequence reads were clipped from 39 adapters using fastx_clip-
per (http://hannonlab.cshl.edu/fastx_toolkit/). Reads in which
the adapter sequence (CTGTAGGCACCATCAATCGT) could
not be detected were discarded. Only the clipped 19–30 nt reads
were retained. Sequence reads were first matched against the
Drosophila genome (v5.37) using Bowtie (http://bowtie-bio.
sourceforge.net/index.shtml). Reads not matching the Drosophila
genome were then matched against the published Nora virus
sequence (NC_007919.3, isolate Umea˚ 2007), allowing one
mismatch during alignment. Viral small RNAs were then used
to reconstitute a small RNA-based consensus genome sequence
(rNora virus, JX220408) using Paparazzi [21] with NC_007919.3
as a starting viral reference genome. Distributions of Nora virus
small RNA sizes were computed by parsing the Bowtie outputs
with a python script (available upon request). Small RNA profiles
were generated by collecting the 21-nt reads that matched the
rNora virus sequence allowing one mismatch, and their frequency
relative to their 59 position in the rNora virus (+) or (2) genomic
strand was plotted in R. siRNA duplex signatures were calculated
according to an algorithm developed to calculate overlap in
piRNA sequence reads [47,48]. The distribution of siRNA
overlaps was computed by collecting the 21-nt rNora virus RNA
reads whose 59 ends overlapped with another 21-nt read on the
opposite strand. For each possible overlap of 1 to 21 nt (i), the
number of read pairs (O) was counted and converted to a Z-score
with the formula Z(i) = (O(i)-mean(O))/standard deviation (O).
Small RNA sequences were deposited to the Sequence Read
Archive (SRA) at the National Center for Biotechnology
Information (NCBI) under accession number SRA054241.
Cell culture and viruses
Drosophila S2 cells were cultured at 25uC in Schneider’s medium
(Invitrogen) supplemented with 10% heat inactivated fetal calf
serum, 50 U/mL penicillin, and 50 mg/mL streptomycin (Invitro-
Figure 6. VP1 interferes with the effector phase of the RNAi pathway. (A) Mobility shift assays for binding of viral RNAi suppressor proteins
to siRNAs. Radiolabeled siRNAs were incubated in buffer (lane 1) or with decreasing amounts of recombinant MBP-VP1DN284 (lanes 2–5), MBP (lanes
6–9), and MBP-NS3 (lane 10–13). Ten-fold dilutions were used, starting at 2 mM for MBP-VP1DN284 (lane 2) and 2.6 mM for MBP (lane 6). MBP-NS3 was
tested in two-fold dilutions (highest concentration of 8 mM, lane 10). RNA mobility shifts were analyzed on an 8% native polyacrylamide gel. (B) RISC
Slicer assay in Drosophila embryo lysate. Lysates were incubated with non-targeting control siRNA (Ctrl, lane 1) or with Fluc siRNA (lanes 2–4) in the
absence (lane 2) or presence of recombinant MBP-VP1DN284 (lane 3) or MBP (lane 4). RISC cleavage products were analyzed on an 8% denaturing
polyacrylamide gel. Slicer assay is representative for two independent experiments.
doi:10.1371/journal.ppat.1002872.g006
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Figure 7. VP1 inhibits Slicer activity of pre-assembled mature RISC. (A) Schematic overview of the two experimental conditions of the Slicer
assay designed to monitor the effect of recombinant (rec.) proteins on RISC assembly and Slicer activity (top) or on Slicer activity of pre-assembled
RISC (bottom) (B) Slicer assays in Drosophila embryo lysates. RISC activity was analyzed in the presence of a non-targeting control siRNA (lane 1) or a
specific Fluc siRNA (lane 2–10). Recombinant proteins were added before (lanes 3–6) or after (lanes 7–10) assembly of RISC as indicated. As a control
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gen). DCV was cultured and titered on S2 cells as described
previously [6]. For the production of recombinant SINV, the
coding sequence of either GFP or the N-terminal V5 epitope
tagged VP1DN351 was cloned into the XbaI site of the double
subgenomic pTE3’2J vector [49]. The resulting plasmids were
linearized by XhoI restriction, purified and used as template for in
vitro transcription using the mMESSAGE mMACHINE SP6 High
Yield Capped RNA Transcription kit (Ambion). In vitro transcribed
RNA was purified using the RNeasy kit (Qiagen) and transfected
into BHK cells. Viral titers in the supernatant were determined by
plaque assay on BHK cells.
RNAi reporter assay in S2 cells
RNAi reporter assays were performed as described previously
using 25 ng pMT-GL3, 6 ng pMT-Ren, and 25 ng suppressor
plasmid per well of a 96-well plate [50]. Plasmids encoding Nora
virus cDNA constructs were generated as described in Protocol S1.
Flies and fly injections
Flies were maintained on standard medium at 25uC with a
light/dark cycle of 12 hours/12 hours. Fly stocks that were used
for Sindbis virus infection and for preparation of embryo lysate
were cleared of Wolbachia and endogenous virus infection (see
Protocol S1). We used the following fly stocks and alleles: UAS-
CrPV 1A [13,51], AGO2321 [52], Dcr-2L811fsX [53], thRNAi [24,25].
The coding sequences of the full-length VP1 and the inactive
VP1DC74 mutant with an N-terminal V5 epitope tag were cloned
into the pUAST vector using the SacII and XbaI restriction sites
[54]. The resulting plasmids were microinjected into Drosophila
w1118 embryos to generate transgenic fly lines (Bestgene Inc). Virus
infections of adult female flies were performed as described
previously using 5,000 PFU of recombinant SINV [6]. Survival
was monitored daily. In vivo RNAi experiments were performed by
crossing GMR-Gal4, UAS-thRNAi/CyO virgins (Meyer et al., 2006)
with UAS-VSR/TM3 Sb flies. The eye phenotype was monitored in
two- to four-day-old male F1 offspring lacking the CyO and TM3
Sb balancers.
Production of recombinant proteins in E. coli
The GST and MBP fusion proteins were purified from E. coli as
described in Protocol S1. Purified recombinant proteins were
dialyzed against dialysis buffer (20 mM Tris-HCl, 0.5 mM EDTA,
5 mM MgCl2, 1 mM DTT, 140 mM NaCl, 2.7 mM KCl)
Recombinant proteins were stored as aliquots at 280uC in dialysis
buffer containing 30% glycerol.
Gel mobility shift, Dicer and Slicer assays
Gel mobility shift assays were performed as described [6].
Briefly, uniformly radio-labeled 113 nt long dsRNA (50 cps/
reaction) or end-labeled siRNAs (200 cps/reaction) were incubat-
ed with purified recombinant protein for 30 minutes at room
temperature. Samples were then separated on an 8% native
polyacrylamide gel and exposed to a Kodak Biomax XAR film.
Dicer and Slicer assays were performed according to the protocol
of Haley and colleagues with minor modifications, described in
Protocol S1 [30]. For Slicer assays with the methylated duplex, Fluc
guide strand 59- UCG AAG UAC UCA GCG UAA GU[mU] and
passenger strand 59- CUU ACG CUG AGU ACU UCG AUU
were annealed by incubating 20 mM of each siRNA strand in
annealing buffer (100 mM potassium acetate, 30 mM HEPES-
KOH at pH 7.4, 2 mM magnesium acetate) for 1 min at 90uC,
followed by incubation for 1 hour at 37uC. For guide strand loading
of RISC, embryo lysates were incubated with Fluc single-stranded
guide strand RNA at a final concentration of 10 mM. Radiolabeled
probes and target RNA for gel shift and Slicer assays are described
in Protocol S1.
Supporting Information
Figure S1 VP1 is unable to suppress the miRNA
pathway. A firefly luciferase (Fluc) construct containing the
par6 39UTR, a target for miRNA1 (Fluc-par6), was co-transfected
with plasmids encoding Renilla luciferase (Rluc) and either Nora
virus VP1 or the inactive VP1DC74 mutant. Fluc-par6 expression
was silenced by co-transfecting a plasmid encoding pri-miRNA1,
whereas a pri-miRNA12 expressing construct was used as a negative
control. AGO1 or AGO2 gene expression was knocked down by co-
transfection of dsRNA targeting these genes (dsAGO1 and
dsAGO2, respectively). Expression of Fluc and Rluc was induced
two days after transfection, and reporter activities were measured
three days after transfection. Rluc activity was used to normalize
Fluc activity within each sample, and data were normalized to the
pri-miR12 treated sample. Bars represent averages and standard
deviations of biological triplicates. A representative graph of two
independent experiments is shown. The numbers represent p-values
relative to pri-miR1 treated vector control samples in a two-tailed
Student’s t-test assuming equal variances.
(TIF)
Figure S2 Alignment of VP1 sequences from different
Nora virus isolates. Alignment of VP1 sequences of Nora virus
isolate Umea˚ 2007 (accession number GQ257737) and Nora virus
sequences from infected fly stocks from our own laboratory
(isolates NL1 and NL2, GenBank accession number JQ288019
and JQ288020). We analyzed VP1 sequences in a total of eight
Nora virus infected fly stocks. Five VP1 sequences were identical to
NL1, one was the NL2 sequence, and two stocks contained a
mixed population of Nora virus sequences. These eight stocks were
obtained from five different laboratories or stock centers.
However, they have been maintained in our laboratory before
we tested them for Nora virus infection, and we cannot exclude the
possibility that they became infected in our laboratory. Although
we therefore cannot infer overall virus diversity from these data,
they do indicate that VP1 is a conserved protein. The FR1 isolate
is the Nora virus genome that was reconstituted from small RNA
sequences from wildtype w1118 flies from a laboratory based in
France (GenBank accession number JX220408).
(TIF)
for possible buffer effects, recombinant protein was substituted by protein storage buffer (lanes 1 and 2). (C) Western blot showing the endogenous
AGO2 protein levels in embryo lysate after incubation for 2 hours with the indicated recombinant proteins. The blot was developed with AGO2
antibody 4D2. (D) Slicer assay using an siRNA with a 29-O-methylated guide strand. A non-modified control siRNA (lane 1) or a Fluc siRNA duplex
containing a 29-O-methyl group at the 39 terminal nucleotide of the guide strand (lanes 2–6) was added to embryo lysate 30 minutes prior to the
addition of the indicated recombinant proteins. (E) Slicer assay using a 29-O-methylated simplex guide RNA. A control siRNA duplex (lane 1) or a
single-stranded Fluc specific guide strand with a 29-O-methyl group at the 39 terminal nucleotide (lane 2–6) was added prior to the addition of the
indicated recombinant proteins. (F) Slicer assays in the presence or absence of ATP. Embryo lysate was incubated with a control siRNA (lanes 1 and 6)
or a specific Fluc siRNA (lanes 2–5 and 7–10). ATP was then depleted (lanes 1–5) or depleted and subsequently regenerated (lanes 6–10) and Slicer
activity was monitored. An asterisk (*) indicates a non-specific band appearing in RISC assays under ATP depleted conditions.
doi:10.1371/journal.ppat.1002872.g007
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Figure S3 Nucleotide and protein sequence of full-
length and VP1 mutants fused to V5-His tag at the N-
terminus. Nucleotide and amino acid sequence of V5 epitope
and Histidine (His) tagged full-length VP1 sequence (VP1FL). A
linker sequence between the His tag and VP1 was created to
facilitate cloning. Start and stop sites of the respective N- and C-
terminal deletion mutants of VP1 are indicated. The VP1 deletion
mutants were fused to the V5-His tag in an identical way as the
VP1FL construct.
(TIF)
Figure S4 Nora virus VP1 is unable to bind long dsRNA
or to interfere with Dcr-2 activity. (A) Mobility shift assay of
suppressor proteins with long dsRNA. Uniformly radiolabeled
long dsRNA was incubated for 30 minutes with buffer (lane 1) or
recombinant MBP-VP1DN284 (lanes 2–4), MBP (lanes 5–7), GST-
DCV 1A (lanes 8–10) or GST (lanes 11–13). Ten-fold dilutions of
recombinant protein were used starting from the following
concentrations: MBP-VP1DN284 (2 mM, lane 2), MBP (2.6 mM,
lane 5), GST-DCV 1A (1 mM, lane 8), and GST (2.24 mM, lane
11). RNA mobility shifts were analyzed on an 8% native
polyacrylamide gel. (B) Dicer activity in S2 cell extract in the
presence of viral suppressor proteins. Uniformly radiolabeled long
dsRNA was incubated in S2 cell extract for 3 hours with buffer
(lane 3) or the indicated recombinant proteins. Two-fold dilutions
were used for MBP-VP1DN284 (lanes 4–7, highest concentration
1.1 mM) and MBP (lanes 8–11, highest concentration 4.2 mM).
Two independent preparations of GST-DCV 1A were used (lane
12, concentration of 0.54 mM and lane 13, concentration of
0.03 mM). GST was used at a concentration of 1.2 mM (lane 14).
As size markers, dsRNA input (lane 1) and end-labelled siRNAs
(lane 2) were used. Dicer products were analyzed on a 12%
denaturing polyacrylamide gel.
(TIF)
Figure S5 ATP depletion during Slicer assay. (A) Sche-
matic representation of the protocol used to deplete (2ATP) or to
regenerate ATP after initial depletion (+ATP) for Slicer assays of
Figure 7F. For RISC loading, Drosophila embryo lysate was
incubated with an siRNA for 30 minutes under standard
conditions. Subsequently, N-ethylmaleimide (NEM) was added
in both conditions to inhibit the ATP regenerating activity of
creatine kinase. After incubating the reactions for 10 minutes on
ice, DTT was added to quench the NEM in both conditions.
Hexokinase, glucose, and milliQ water (MQ) were added in the –
ATP protocol to deplete the pool of ATP. For the +ATP
condition, Hexokinase was substituted by hexokinase buffer, and
MQ was substituted for Creatine kinase to restore the ATP
regenerating activity. Subsequently, the reactions were incubated
for 30 minutes after which recombinant protein (rec. protein) was
added. Following another 30 minutes incubation period, the 32P-
cap-labelled RNA was added to the reaction, after which the
incubation was continued for another 2 hours. Subsequently,
reactions were analyzed on a polyacrylamide gel. (B) ATP
concentrations before and after the Slicer assay under –ATP
and +ATP conditions. ATP levels were measured at the moment
of target RNA addition (0 hrs) or after 2 hours of incubation with
target RNA. For ATP concentration measurements, recombinant
protein was substituted for protein storage buffer, and target RNA
was substituted for MQ. ATP levels were measured using the
Celltiter-Glo Luminescent Cell Viability Assay (Promega) accord-
ing to the manufacturer’s protocol.
(TIF)
Protocol S1 Extended and supplemental methods for
molecular cloning, miRNA sensor assay, clearance of
Wolbachia and endogenous viruses from fly stocks,
production of recombinant proteins in E. coli, produc-
tion of radio-labeled probes and target RNA, Dicer and
Slicer assays.
(DOC)
Text S1 Nora virus VP1 is unable to suppress the
miRNA pathway.
(DOC)
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